Triple
T6004712
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | onasemnogene abeparvovec |
E133681
|
entity |
| Predicate | hasInternationalNonproprietaryName |
P24556
|
FINISHED |
| Object | onasemnogene abeparvovec |
E133681
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: onasemnogene abeparvovec | Statement: [onasemnogene abeparvovec, hasInternationalNonproprietaryName, onasemnogene abeparvovec]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: onasemnogene abeparvovec Context triple: [onasemnogene abeparvovec, hasInternationalNonproprietaryName, onasemnogene abeparvovec]
-
A.
onasemnogene abeparvovec
chosen
Onasemnogene abeparvovec is a gene therapy medication that delivers a functional copy of the SMN1 gene to treat infants and young children with certain forms of spinal muscular atrophy.
-
B.
Spinraza
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
C.
Aduhelm
Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
-
D.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
E.
SMN2
SMN2 is a human gene that produces a backup form of survival motor neuron protein and is a key therapeutic target in spinal muscular atrophy.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c00872444c8190bfaf1739dcec765c |
completed | March 22, 2026, 3:19 p.m. |
| NER | Named-entity recognition | batch_69c04f10d18081908c351170b7f58d3d |
completed | March 22, 2026, 8:20 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c1088f5c84819094e4696c24c4dd79 |
completed | March 23, 2026, 9:31 a.m. |
Created at: March 22, 2026, 4:06 p.m.